Leap Therapeutics DKN-01 combo shows 11.3-month median PFS and 68% ORR in first-line gastric cancer at ESMO

CYPHERPUNK TECHNOLOGIES INC.

Median PFS 11.3 months in overall first-line GEA patients in DisTinGuish study, exceeding benchmarks.
ORR 68% overall, 90% in DKK1-high, 79% in PD-L1-low subgroups.
Median OS not mature; 44% deceased as of June 30, 2022 cut; enrollment ongoing for randomized Part C.
WAKING study (DKN-01 + atezolizumab) in 2nd/3rd-line OGA: 18 enrolled, DCR 50%, 1 PR; safety tolerable.
Appointed Richard Schilsky, MD (former ASCO CMO) to Board effective Sept 1, 2022.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Richard Schilsky

Class I director

CYPH · CYPHERPUNK TECHNOLOGIES INC.

Effective: 2022-09-01
Filed: September 7, 2022, 7:59 PM ET

On September 1, 2022, the Board of Directors (the “Board”) of Leap Therapeutics, Inc. (the “Company”) appointed Richard Schilsky, M.D. as a Class I director of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Schilsky was appointed as Class I director at CYPHERPUNK TECHNOLOGIES INC..

Action: appointed
Role: Class I director

Exact text from the filing

On September 1, 2022, the Board of Directors (the “Board”) of Leap Therapeutics, Inc. (the “Company”) appointed Richard Schilsky, M.D. as a Class I director of the Board.

View on SEC.gov

CYPHERPUNK TECHNOLOGIES INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-098035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.